Yaozhen Pan

450 total citations
22 papers, 284 citations indexed

About

Yaozhen Pan is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Yaozhen Pan has authored 22 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 10 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Yaozhen Pan's work include Pancreatic and Hepatic Oncology Research (5 papers), Cancer, Hypoxia, and Metabolism (3 papers) and RNA modifications and cancer (3 papers). Yaozhen Pan is often cited by papers focused on Pancreatic and Hepatic Oncology Research (5 papers), Cancer, Hypoxia, and Metabolism (3 papers) and RNA modifications and cancer (3 papers). Yaozhen Pan collaborates with scholars based in China and Canada. Yaozhen Pan's co-authors include Chao Yu, Ling Chen, Lei Zhan, Chengyi Sun, Zhiwei He, Hong Zhang, Hong Zhang, Songbai Liu, Chengyi Sun and Changhao Zhu and has published in prestigious journals such as Journal of Clinical Oncology, Cell Death and Disease and Biomedicine & Pharmacotherapy.

In The Last Decade

Yaozhen Pan

20 papers receiving 281 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yaozhen Pan China 7 176 92 91 46 44 22 284
Atsutaka Masuda Japan 9 142 0.8× 92 1.0× 85 0.9× 27 0.6× 51 1.2× 19 279
Christine Pich-Bavastro Switzerland 11 159 0.9× 109 1.2× 101 1.1× 79 1.7× 44 1.0× 16 325
Aiping Ding China 10 185 1.1× 88 1.0× 89 1.0× 47 1.0× 75 1.7× 20 293
Judit López‐Luque Spain 8 179 1.0× 70 0.8× 95 1.0× 80 1.7× 56 1.3× 8 368
Xianghong Yang China 13 274 1.6× 208 2.3× 99 1.1× 43 0.9× 29 0.7× 24 371
Tianliang Xia China 12 241 1.4× 125 1.4× 119 1.3× 44 1.0× 81 1.8× 21 366
Shufen Zhao China 10 170 1.0× 106 1.2× 83 0.9× 29 0.6× 97 2.2× 30 316
Shaowei Song China 10 147 0.8× 101 1.1× 149 1.6× 88 1.9× 37 0.8× 21 315
Deyang Li China 12 204 1.2× 110 1.2× 52 0.6× 43 0.9× 35 0.8× 23 310
Kunming Wen China 13 287 1.6× 151 1.6× 136 1.5× 32 0.7× 70 1.6× 29 417

Countries citing papers authored by Yaozhen Pan

Since Specialization
Citations

This map shows the geographic impact of Yaozhen Pan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yaozhen Pan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yaozhen Pan more than expected).

Fields of papers citing papers by Yaozhen Pan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yaozhen Pan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yaozhen Pan. The network helps show where Yaozhen Pan may publish in the future.

Co-authorship network of co-authors of Yaozhen Pan

This figure shows the co-authorship network connecting the top 25 collaborators of Yaozhen Pan. A scholar is included among the top collaborators of Yaozhen Pan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yaozhen Pan. Yaozhen Pan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Lianxin, Jiabei Wang, Tongsen Zheng, et al.. (2025). SHR-8068 plus adebrelimab and bevacizumab for advanced hepatocellular carcinoma (aHCC): A phase 1b/2 study.. Journal of Clinical Oncology. 43(16_suppl). 4093–4093. 1 indexed citations
2.
Hou, Junyi, Peng Liu, Songbai Liu, et al.. (2024). TAGLN2 targeted control of ARPC5-mediated activation of the MEK/ERK signaling pathway influences the proliferation, invasion, and metastasis of pancreatic cancer cells. Cellular Signalling. 120. 111227–111227. 4 indexed citations
3.
Ren, Likun, Shaojie Chen, Peng Liu, et al.. (2024). Unveiling the role of PYGB in pancreatic cancer: a novel diagnostic biomarker and gene therapy target. Journal of Cancer Research and Clinical Oncology. 150(3). 127–127.
4.
5.
Zhu, Changhao, Peng Liu, Songbai Liu, et al.. (2024). PELI1: key players in the oncogenic characteristics of pancreatic Cancer. Journal of Experimental & Clinical Cancer Research. 43(1). 91–91. 5 indexed citations
6.
Liu, Songbai, et al.. (2023). Analysis and validation of the potential of the MYO1E gene in pancreatic adenocarcinoma based on a bioinformatics approach. Oncology Letters. 26(1). 285–285. 2 indexed citations
7.
Liu, Peng, Songbai Liu, Changhao Zhu, et al.. (2023). The deubiquitinating enzyme MINDY2 promotes pancreatic cancer proliferation and metastasis by stabilizing ACTN4 expression and activating the PI3K/AKT/mTOR signaling pathway. Frontiers in Oncology. 13. 1169833–1169833. 7 indexed citations
8.
Wang, Xing, Ying Li, Yongning Li, et al.. (2022). FBXW7 Reduces the Cancer Stem Cell-Like Properties of Hepatocellular Carcinoma by Regulating the Ubiquitination and Degradation of ACTL6A. Stem Cells International. 2022. 1–26. 5 indexed citations
9.
Li, Ying, et al.. (2022). FAM126A interacted with ENO1 mediates proliferation and metastasis in pancreatic cancer via PI3K/AKT signaling pathway. Cell Death Discovery. 8(1). 248–248. 16 indexed citations
10.
11.
Liu, Songbai, Peng Liu, Xing Wang, et al.. (2022). Identification and validation of a potential key gene SGOL1 for poor prognosis in hepatocellular carcinoma based on a bioinformatics approach. Frontiers in Oncology. 12. 1043161–1043161. 2 indexed citations
12.
Wang, Xing, et al.. (2021). Endoscopic management of biliary ascariasis: A case report. World Journal of Clinical Cases. 9(20). 5695–5700. 3 indexed citations
13.
Zhu, Changhao, et al.. (2021). Asiatic Acid Encapsulated Exosomes of Hepatocellular Carcinoma Inhibit Epithelial-Mesenchymal Transition Through Transforming Growth Factor Beta/Smad Signaling Pathway. Journal of Biomedical Nanotechnology. 17(12). 2338–2350. 9 indexed citations
14.
Zhang, Hong, Yaozhen Pan, Chao Yu, et al.. (2019). LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway. Cell Death and Disease. 10(3). 230–230. 121 indexed citations
15.
Chen, Zili, Yifei Ma, Yaozhen Pan, et al.. (2018). MiR-1297 suppresses pancreatic cancer cell proliferation and metastasis by targeting MTDH. Molecular and Cellular Probes. 40. 19–26. 22 indexed citations
16.
Pan, Yaozhen, Lei Zhan, Ling Chen, et al.. (2018). POU5F1B promotes hepatocellular carcinoma proliferation by activating AKT. Biomedicine & Pharmacotherapy. 100. 374–380. 28 indexed citations
17.
Chen, Weiwei, et al.. (2018). Chemoprotective Efficacy of Salvianolic Acid B via Triggering Apoptosis in MCF-7 Human Breast Cancer Cells. International Journal of Pharmacology. 15(1). 110–115. 5 indexed citations
18.
Xin, Xiaoyan, et al.. (2015). Telomerase Activity as a Marker for Differential Diagnosis of Pancreatic Adenocarcinoma: A Systematic Review and Meta-Analysis. The International Journal of Biological Markers. 31(2). 126–137. 5 indexed citations
19.
Yu, Chao, Lei Zhan, Jianxin Jiang, et al.. (2014). KAP-1 is overexpressed and correlates with increased metastatic ability and tumorigenicity in pancreatic cancer. Medical Oncology. 31(7). 25–25. 35 indexed citations
20.
Sun, Cheng-Yi & Yaozhen Pan. (2008). Advances in pathogenesis of hyperlipidemic acute pancreatitis and its diagnosis and treatment. World Chinese Journal of Digestology. 16(4). 343–343. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Atsutaka Masuda Breakdown of academic impact, for papers by Christine Pich-Bavastro Breakdown of academic impact, for papers by Aiping Ding Breakdown of academic impact, for papers by Judit López‐Luque Breakdown of academic impact, for papers by Xianghong Yang Breakdown of academic impact, for papers by Tianliang Xia Breakdown of academic impact, for papers by Shufen Zhao Breakdown of academic impact, for papers by Shaowei Song Breakdown of academic impact, for papers by Deyang Li Breakdown of academic impact, for papers by Kunming Wen
Rankless by CCL
2026